David Veitch
Chief Executive Officer bei BASILEA PHARMACEUTICA AG
Vermögen: 54 341 $ am 31.03.2024
Profil
David Veitch is currently the Chief Executive Officer at Basilea Pharmaceutica AG since 2018.
Prior to this, he was the President-European Operations at Savient Pharmaceuticals, Inc. from 2012 to 2013.
He also served as the SVP-European Marketing & Brand Commercialization at Bristol-Myers Squibb Pharmaceuticals Ltd.
from 2007 to 2011.
Mr. Veitch completed his undergraduate degree at the University of Bristol.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BASILEA PHARMACEUTICA AG
0,01% | 31.12.2022 | 1 300 ( 0,01% ) | 54 341 $ | 31.03.2024 |
Aktive Positionen von David Veitch
| Unternehmen | Position | Beginn |
|---|---|---|
| BASILEA PHARMACEUTICA AG | Chief Executive Officer | 19.04.2018 |
Ehemalige bekannte Positionen von David Veitch
| Unternehmen | Position | Ende |
|---|---|---|
| SAVIENT PHARMACEUTICALS INC | Corporate Officer/Principal | 01.01.2013 |
Bristol-Myers Squibb Pharmaceuticals Ltd.
 Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Corporate Officer/Principal | 01.01.2011 |
Ausbildung von David Veitch
| University of Bristol | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BASILEA PHARMACEUTICA AG | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Health Technology |
